Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05308264 · ClinicalTrials.gov registry record · Phase 1
Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)
A Phase 1 study of Low Risk Myelodysplastic Syndromes, sponsored by Rigel Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 86
- Enrollment target
- 15
- Study locations
NCT05308264 is a Phase 1 study of Low Risk Myelodysplastic Syndromes that is actively recruiting participants, run by Rigel Pharmaceuticals. The registered enrollment target is 86 participants. The trial reports 15 study locations across 9 states.
The verdict
NCT05308264, a Phase 1 study of Low Risk Myelodysplastic Syndromes, is actively recruiting participants, sponsored by Rigel Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 86 participants
- Enrollment target
- 15
- Study locations
Study Summary
Phase 1b Study of R289 in Patients with Lower-risk Myelodysplastic Syndromes (LR MDS)
Conditions Studied
Interventions
- DRUG R906289 Monosodium (R289 Na)
Study Locations (15)
California
- University of California, Los Angeles - Los Angeles
- University of California, Irvine - Orange
- Stanford Cancer Institute - Palo Alto
Florida
- University of Miami - Miami
- Mount Sinai Medical Center - Miami Beach
New Jersey
- Oncology Clinical Research Referral Office - Hackensack
- Rutgers Cancer Institute of New Jersey - New Brunswick
Ohio
- Cleveland Clinic - Cleveland
- The Ohio State University Comprehensive Cancer Center - Columbus
Texas
- University of Texas, Southwestern - Dallas
- MD Anderson Cancer Center - Houston
Missouri
- WashU Medicine - St Louis
New York
- Ichan School of Medicine at Mount Sinai - New York
North Carolina
- Duke Cancer Institute - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2022-09-12 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05308264
The ClinicalTrials.gov registry entry for NCT05308264 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rigel Pharmaceuticals, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Low Risk Myelodysplastic Syndromes appearing as the primary indexed condition, and to 1 intervention - of which R906289 Monosodium (R289 Na) is the first listed.
NCT05308264 reports 15 study locations spanning 9 distinct geographic areas - top geographies include California, Florida, New Jersey.
Frequently Asked Questions
What is clinical trial NCT05308264 about?
NCT05308264 is a clinical study titled "Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)". Phase 1b Study of R289 in Patients with Lower-risk Myelodysplastic Syndromes (LR MDS)
What is the current status of trial NCT05308264?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 86 participants. The study started on 2022-09-12. Estimated completion is 2026-12.
What conditions does trial NCT05308264 study?
This clinical trial studies the following conditions: Low Risk Myelodysplastic Syndromes.
What interventions are being tested in trial NCT05308264?
The interventions under investigation include: R906289 Monosodium (R289 Na) (DRUG).
Who is sponsoring clinical trial NCT05308264?
This trial is sponsored by Rigel Pharmaceuticals, which has 22 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05308264 being conducted?
This trial has 15 study locations across California, Florida, Missouri, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.